1-20 of 23
Lisa A. Hammond
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer

Chris H. Takimoto, Lisa A. Hammond-Thelin, Jane E. Latz, Leonardo Forero, Muralidhar Beeram, Bahram Forouzesh, Johann de Bono, Anthony W. Tolcher, Amita Patnaik, Pamela Monroe, Leslie Wood, Karen B. Schneck, Romnee Clark, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (9): 2675–2683.
https://doi.org/10.1158/1078-0432.CCR-06-2393
Published: 01 May 2007
View articletitled, Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer
Open the PDF for Phase I and Pharmacokinetic Study of Pemetrexed with High-Dose Folic Acid Supplementation or Multivitamin Supplementation in Patients with Locally Advanced or Metastatic Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies

Eric K. Rowinsky, Muralidhar Beeram, Lisa A. Hammond, Garry Schwartz, Johann De Bono, Baharam Forouzesh, Quincy Chu, Jane E. Latz, Shengyan Hong, William John, Binh Nguyen
Journal: Clinical Cancer Research
Clin Cancer Res (2007) 13 (2): 532–539.
https://doi.org/10.1158/1078-0432.CCR-06-1606
Published: 25 January 2007
View articletitled, A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of Pemetrexed Plus Irinotecan in Patients with Advanced Solid Malignancies in another window
Journal Articles

Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors

Amita Patnaik, Debra Wood, Anthony W. Tolcher, Marta Hamilton, Jeffrey I. Kreisberg, Lisa A. Hammond, Garry Schwartz, Muralidhar Beeram, Manuel Hidalgo, Monica M. Mita, Julie Wolf, Paul Nadler, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (24): 7406–7413.
https://doi.org/10.1158/1078-0432.CCR-06-1886
Published: 22 December 2006
View articletitled, Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors

Alain C. Mita, Lisa A. Hammond, Peter L. Bonate, Geoffrey Weiss, Heather McCreery, Samira Syed, Mitchell Garrison, Quincy S.C. Chu, Johann S. DeBono, Christopher B. Jones, Steve Weitman, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (17): 5207–5215.
https://doi.org/10.1158/1078-0432.CCR-06-0179
Published: 01 September 2006
View articletitled, Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride (ILX651), a Third-Generation Dolastatin-15 Analogue, Administered Weekly for 3 Weeks Every 28 Days in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction

Larry J. Schaaf, Lisa A. Hammond, Stuart J. Tipping, Richard M. Goldberg, Rakesh Goel, John G. Kuhn, Langdon L. Miller, Linda D. Compton, Laura A. Cisar, Gary L. Elfring, Gabriela Gruia, J. Patrick McGovren, Nicoletta Pirotta, Donghua Yin, Amarnath Sharma, Barbara A. Duncan, Mace L. Rothenberg
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (12): 3782–3791.
https://doi.org/10.1158/1078-0432.CCR-05-2152
Published: 15 June 2006
View articletitled, Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction
Open the PDF for Phase 1 and Pharmacokinetic Study of Intravenous Irinotecan in Refractory Solid Tumor Patients with Hepatic Dysfunction in another window
Journal Articles

Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors

Alejandro D. Ricart, Lisa A. Hammond, John G. Kuhn, Chris H. Takimoto, Andrew Goetz, Bahram Forouzesh, Leonardo Forero, Jose L. Ochoa-Bayona, Kristin Berg, Anthony W. Tolcher, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (24): 8728–8736.
https://doi.org/10.1158/1078-0432.CCR-05-1572
Published: 16 December 2005
View articletitled, Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of Sequences of the Rebeccamycin Analogue NSC 655649 and Cisplatin in Patients with Advanced Solid Tumors in another window
Journal Articles

A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors

Scot Ebbinghaus, Eric Rubin, Evan Hersh, Lee D. Cranmer, Peter L. Bonate, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7807–7816.
https://doi.org/10.1158/1078-0432.CCR-05-0909
Published: 08 November 2005
View articletitled, A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for A Phase I Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously Daily for 5 Consecutive Days Every 3 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors

Casey Cunningham, Leonard J. Appleman, Miora Kirvan-Visovatti, David P. Ryan, Eileen Regan, Svetislava Vukelja, Peter L. Bonate, Francis Ruvuna, Robert J. Fram, Antti Jekunen, Steve Weitman, Lisa A. Hammond, Joseph P. Eder, Jr.
Journal: Clinical Cancer Research
Clin Cancer Res (2005) 11 (21): 7825–7833.
https://doi.org/10.1158/1078-0432.CCR-05-0058
Published: 08 November 2005
View articletitled, Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors
Open the PDF for Phase I and Pharmacokinetic Study of the Dolastatin-15 Analogue Tasidotin (ILX651) Administered Intravenously on Days 1, 3, and 5 Every 3 Weeks in Patients with Advanced Solid Tumors in another window
Journal Articles

ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas

Johann S. de Bono, Anthony W. Tolcher, Andre Forero, Gertrude F. A. Vanhove, Chris Takimoto, Robert J. Bauer, Lisa A. Hammond, Amita Patnaik, Mark L. White, Sui Shen, Muhammad B. Khazaeli, Eric K. Rowinsky, Albert F. LoBuglio
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (22): 7555–7565.
https://doi.org/10.1158/1078-0432.CCR-04-0729
Published: 29 November 2004
View articletitled, ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas
Open the PDF for ING-1, a Monoclonal Antibody Targeting Ep-CAM in Patients with Advanced Adenocarcinomas in another window
Journal Articles

Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study

Emiliano Calvo, Anthony W. Tolcher, Lisa A. Hammond, Amita Patnaik, Johan S. de Bono, Irene A. Eiseman, Stephen C. Olson, Peter F. Lenehan, Heather McCreery, Patricia LoRusso, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (21): 7112–7120.
https://doi.org/10.1158/1078-0432.CCR-04-1187
Published: 08 November 2004
View articletitled, Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study
Open the PDF for Administration of CI-1033, an Irreversible Pan-erbB Tyrosine Kinase Inhibitor, Is Feasible on a 7-Day On, 7-Day Off Schedule: A Phase I Pharmacokinetic and Food Effect Study in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties

Samira Syed, Chris Takimoto, Manuel Hidalgo, Jinee Rizzo, John G. Kuhn, Lisa A. Hammond, Garry Schwartz, Anthony Tolcher, Amita Patnaik, S. Gail Eckhardt, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (19): 6512–6521.
https://doi.org/10.1158/1078-0432.CCR-04-0804
Published: 08 October 2004
View articletitled, A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties
Open the PDF for A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties in another window
Journal Articles

A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer

Anthony W. Tolcher, John Kuhn, Garry Schwartz, Amita Patnaik, Lisa A. Hammond, Ian Thompson, Howard Fingert, David Bushnell, Shazli Malik, Jeffrey Kreisberg, Elzbieta Izbicka, Leslie Smetzer, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 5048–5057.
https://doi.org/10.1158/1078-0432.CCR-03-0701
Published: 05 August 2004
View articletitled, A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer
Open the PDF for A Phase I Pharmacokinetic and Biological Correlative Study of Oblimersen Sodium (Genasense, G3139), an Antisense Oligonucleotide to the Bcl-2 mRNA, and of Docetaxel in Patients with Hormone-Refractory Prostate Cancer in another window
Journal Articles

Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies

Quincy Siu-Chung Chu, Lisa A. Hammond, Garry Schwartz, Leonel Ochoa, Sun-Young Rha, Louis Denis, Kathleen Molpus, Brian Roedig, Stephen P. Letrent, Bharat Damle, Arthur P. DeCillis, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (15): 4913–4921.
https://doi.org/10.1158/1078-0432.CCR-04-0469
Published: 05 August 2004
View articletitled, Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies
Open the PDF for Phase I and Pharmacokinetic Study of the Oral Fluoropyrimidine S-1 on a Once-Daily-for-28-Day Schedule in Patients with Advanced Malignancies in another window
Journal Articles

A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms

Lisa A. Hammond, John R. Eckardt, John G. Kuhn, Stanton L. Gerson, Tom Johnson, Lon Smith, Ronald L. Drengler, Elizabeth Campbell, Geoffrey R. Weiss, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2004) 10 (5): 1645–1656.
https://doi.org/10.1158/1078-0432.CCR-03-0174
Published: 10 March 2004
View articletitled, A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms
Open the PDF for A Randomized Phase I and Pharmacological Trial of Sequences of 1,3-bis(2-Chloroethyl)-1-Nitrosourea and Temozolomide in Patients with Advanced Solid Neoplasms in another window
Journal Articles

A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies

Bahram Forouzesh, Chris H. Takimoto, Andrew Goetz, Sami Diab, Lisa A. Hammond, Leslie Smetzer, Garry Schwartz, Robert Gazak, John T. Callaghan, Daniel D. Von Hoff, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (15): 5540–5549.
Published: 03 December 2003
View articletitled, A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmacokinetic Study of ILX-295501, an Oral Diarylsulfonylurea, on a Weekly for 3 Weeks Every 4-Week Schedule in Patients with Advanced Solid Malignancies in another window
Journal Articles

A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies

Amita Patnaik, S. Gail Eckhardt, Elzbieta Izbicka, Anthony A. Tolcher, Lisa A. Hammond, Chris H. Takimoto, Garry Schwartz, Heather McCreery, Andrew Goetz, Masataka Mori, Kazutoyo Terada, Lou Gentner, Mary-Ellen Rybak, Henry Richards, Steven Zhang, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (13): 4761–4771.
Published: 27 October 2003
View articletitled, A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies
Open the PDF for A Phase I, Pharmacokinetic, and Biological Study of the Farnesyltransferase Inhibitor Tipifarnib in Combination with Gemcitabine in Patients with Advanced Malignancies in another window
Journal Articles

A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer

Roy S. Herbst, Lisa A. Hammond, David P. Carbone, Hai T. Tran, Kenneth J. Holroyd, Avinash Desai, Jon I. Williams, B. Nebiyou Bekele, Howard Hait, Victoria Allgood, Stephen Solomon, Joan H. Schiller
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (11): 4108–4115.
Published: 30 September 2003
View articletitled, A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer
Open the PDF for A Phase I/IIA Trial of Continuous Five-Day Infusion of Squalamine Lactate (MSI-1256F) Plus Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer in another window
Journal Articles

A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor

Desirée Hao, Lisa A. Hammond, S. Gail Eckhardt, Amita Patnaik, Chris H. Takimoto, Garry H. Schwartz, Andrew D. Goetz, Anthony W. Tolcher, Heather A. McCreery, Khalid Mamun, Jon I. Williams, Kenneth J. Holroyd, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2465–2471.
Published: 01 July 2003
View articletitled, A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor
Open the PDF for A Phase I and Pharmacokinetic Study of Squalamine, an Aminosterol Angiogenesis Inhibitor in another window
Journal Articles

Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients

Shazli N. Malik, Lillian L. Siu, Eric K. Rowinsky, Linda deGraffenried, Lisa A. Hammond, Jinee Rizzo, Sarah Bacus, Michael G. Brattain, Jeffrey I. Kreisberg, Manuel Hidalgo
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2478–2486.
Published: 01 July 2003
View articletitled, Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients
Open the PDF for Pharmacodynamic Evaluation of the Epidermal Growth Factor Receptor Inhibitor OSI-774 in Human Epidermis of Cancer Patients in another window
Journal Articles

A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies

Mitchell A. Garrison, Lisa A. Hammond, Charles E. Geyer, Jr., Garry Schwartz, Anthony W. Tolcher, Leslie Smetzer, Jose A. Figueroa, Murray Ducharme, John Coyle, Chris H. Takimoto, Robert L. De Jager, Eric K. Rowinsky
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (7): 2527–2537.
Published: 01 July 2003
View articletitled, A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies
Open the PDF for A Phase I and Pharmocokinetic Study of Exatecan Mesylate Administered as a Protracted 21-Day Infusion in Patients with Advanced Solid Malignancies in another window